Immunologically relevant aspects of the new COVID-19 vaccines-an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper.
Eva UntersmayrElisabeth Förster-WaldlMichael BonelliKaan BoztugPatrick M BrunnerThomas EiweggerKathrin EllerLisa GöschlKatharina Grabmeier-PfistershammerWolfram HötzeneckerGalateja JordakievaAlexander R MoschenBirgit PfallerWinfried PicklWalter ReinischUrsula WiedermannLudger KlimekKarl-Christian BergmannRandolf BrehlerWolfgang PfütznerNatalija NovakHans MerkUta RabeWolfgang SchlenterJohannes RingWolfgang WehrmannNorbert MülleneisenHolger WredeThomas FuchsErika Jensen-JarolimPublished in: Allergo journal international (2021)
Despite the need for a patient-specific risk-benefit assessment, the consensus among experts is that patients with immunological diseases in particular benefit from the induced immune protection after COVID-19 vaccination and do not have an increased risk of side effects.